Sobi acquires Dova in $915M hematology franchise play by Kyle Blankenship Monday, September 30, 2019 Swedish pharma Sobi is looking for a leg up in hemotology. Can a $915 million buyout of Dova—and its so-far-underperforming drug Doptelet—do the trick?
Tiny Dova and its Doptelet drug take on Novartis blockbuster by Angus Liu Friday, June 28, 2019 Dova slashes the price of its platelet-boosting drug Doptelet as it gears up to challenge Novartis' Promacta.
Salix inks deal with Dova, 3rd recent deal to boost portfolio by Beth Snyder Bulik Friday, October 5, 2018 Salix's latest deal not only beefs up its own portfolio, but gives Dova a co-promo boost for its newly minted chronic liver disease drug, Doptelet.
